Outline of the Comprehensive
Collaboration Agreement
between Osaka University andChugai Pharmaceutical Co., Ltd.
Executive Vice President of Research and Risk
Management, Osaka University

Yasushi Yagi
1

Pioneering University- Industry “Co-creation”
at Osaka University

The 3 rd stageof universityindustry
collaboration

A new type of university-industry
collaboration, at Osaka University=University-Industry
Co-creation

Approach1Comprehensive collaboration from the stage ofbasic research

Approach2

Nurturing innovative researchers through universityindustry collaboration

Organization-wide development of joint research basedon promising novel ideas originating at the university

2 nd stageJoint research chairs established… 32
Research Alliance Laboratories established … 10（Endowed Chairs established… 46）
As of 1. April, 2016

1 st stage

Technical consultation/ individual collaboration2

Introduction of a new Framework for University-Industry
Collaboration at Osaka University
Comprehensive university-industry collaborationfrom the basic research stage

Endowment

Comprehensive
collaboration

Joint research,commissioned/ contract
researchwith private enterprise

Disclosure of researchachievements

Development toward new
joint research

Utilization of
intellectual property3World Premier International Research Center (WPI) Initiative
Ministry of Education, Culture, Sports, Science and Technology (MEXT), JapanWorld Premier International Research Center (WPI) Initiative
Nine centers established in Japan. IFReC established as an international center for immunology research

4 objectives
ScienceGlobalization

Advancing leading-edge research

Establishing international
research environments

FusionReformCreation interdisciplinary domains

Reform of research
institutions

Immunology Frontier Research Center (IFReC),
Osaka University
IFReC is a world-leading research institute headed by Dr. Shizuo Akira, one of the most prominent
immunologists today. The center leads global immunology research with its 180 researchers including
Dr. Shimon Sakaguchi, well-known for his discovery of regulatory T cells.
The WPI program will transition to a new stage for support from fiscal 2017.

4

Pioneering University- Industry “Co-creation”
at Osaka University

IFReC

researchers

Research based on
promising ideas

Individual collaboration

CompanyA

Individual collaboration

CompanyB

Individual collaboration

CompanyC

Support fromOsaka University
Support from
MEXT
（Competitive）
External researchfunding

Basicresearch

Conventional universityindustry cooperation

5

University- Industry “Co-creation”
from Basic Research at IFReC to Applied Research

IFReC

researchers

Research based on
promising ideas

Support fromOsaka University
Support fromMEXT

ChugaiPharmaceuticalCompanyAIndividual collaboration

CompanyB

Right of first refusal（Competitive）
External researchfunding
Promotion of basic researchwith generous funding

Individual collaboration

Basicresearch

Individual collaboration

ChugaiPharmaIndividual collaboration

ChugaiPharmaDisclosure ofresearch outcomes

Comprehensive collaborationfrom the stage of basic research

Seamless university- industry
cooperation toward appliedresearch

University-Industry Co-Creation
6